We are trying to create innovative next-generation medicine by integrating cutting-edge bio and digital technologies and novel platforms in which many researchers can play active roles
NextGeM was founded to develop next-generation medicine with safety by fully utilizing the potential of hematopoietic stem cells and are trying to provide innovative products or services in this area.
Also, we are developing new diagnostic or treatment method by using AI or digital technologies.We are integrating these bio and digital tech and collaborating with industry and academia in the areas with high unmet medical needs.
Recently, the social and industrial structures have been globalised rapidly and brand-new business models have been emerging with epoch-making innovation in many industries.It is becoming increasingly important to create new value by fully integrating cutting-edge technologies and solutions.
In Japan, it is crucial to innovate and create new value. In order to win the cutthroat global competition, we have to construct a novel platform which is composed of a wide range of stakeholders regardless of industry, academia, government or borders.
We also feel that it is our mission to make a strong team with young excellent people as a role model for young researchers’ careers.
Kiyoharu Hoshino,President
Based on our vision of “realizing next-generation medical innovation through the fusion of cutting-edge bio-digital technologies and creating a platform on which many researchers can work”, we aim to realize “a society in which all people can receive high-quality medical care” and “a society in which innovation is created in a sustainable manner”. We are promoting the following activities.
We believe that these efforts will lead to the achievement of the SDGs, which consist of 17 goals, and we will actively contribute to the achievement of the SDGs through the following specific efforts.
By integrating our cutting-edge bio-digital technologies, we will contribute to a society in which all people can receive high quality medical care by providing innovative solutions in each phase of medical care: prevention, diagnosis, and treatment.
Specifically, we will tackle social and global medical issues such as curative treatment of rare and intractable blood diseases, infertility treatment, and antimicrobial resistance.
By utilizing our cutting-edge bio-digital technology, we aim to achieve a higher level of economic productivity by reforming the medical field, which tends to be labor-intensive, in addition to providing high-value medical services.
Specifically, we will provide high-value medical services by using next-generation biotechnologies related to human long-term hematopoietic stem cells, and promote digital experience (DX) to reduce the burden on medical workplaces by utilizing the latest digital technologies such as AI and cloud computing.
We aim to promote scientific research in the healthcare industry sector in all countries, including developing countries, to improve technological capabilities, and ultimately to develop affordable, high-quality medical technology, by promoting public-private research-driven innovation and by working to improve the number of young R&D workers who will lead the next generation and significantly increase the number of young R&D workers.
Specifically, we will create an environment where people can play an active role in technology creation by collaborating with industry, government, and academia to create innovations on their own, building a collaborative platform to accelerate innovation based on their experiences, and in addition, actively promoting young researchers of the next generation and building a connection platform.
| Company name | NextGeM Inc NextGeM = Next Generation of Medicine |
|---|---|
| President Chairman |
Kiyoharu Hoshino |
| Establishment | April 2016 |
| Tokyo Lab. | 1-5-13 Jinnan, Shibuya-ku, Tokyo 150-0041 |
| Kobe Lab. | 6-3-5 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047 |
| Business purpose | ・Research and development of next generation regenerative medicine innovation using stem cells |
President
Kiyoharu has over 35 years management experience in clinical development and regulatory affairs at Organon Japan, Allergan, Bausch & Lomb Japan, B. Braun Aesculap, and others after graduated from Tokyo University of Science, Faculty of Science Division I. He has been an independent medical device regulatory consultant since 2018. He was appointed CEO of Tama Bio 2021 to 2022. In March 2024, he was appointed as a Director of NexGeM Inc., and President in November 2024.
Co-founder, Chairman
Graduated from Kyoto University, Faculty of Engineering. Gained experience in general trading companies, startups, and private equity before focusing on venture creation and new business development in the healthcare sector.
Director
BSc, Department of Technology, Osaka University. Ph.D., Graduate School of Agriculture, the University of Tokyo. Studied at the University of California, Berkeley, CA, USA. After working at Sumitomo Dainippon Pharma Biotechnology Research Institute and Dainippon Sumitomo Pharma / Genomic Science Laboratories Director, transferred to the Foundation for Biomedical Research and Innovation at Kobe (currently KOBE Biomedical Innovation Cluster) in 2013. Board Director of NextGeM since 2020.
Director
Earned a Ph.D. in Science from Osaka University. Co-founded a drug discovery startup in the U.S. after working at Panasonic Central Research Laboratory. Held senior positions at RIKEN and Osaka University before joining the company as Director.
Advisor
After graduating from faculty of Pharmaceutical Science, Osaka University, Hirosaki joined Fujisawa Pharmaceutical Co., Ltd. (present: Astellas Pharma Inc.). He served as a Director of International Coordination, Clinical Research Center of Fujisawa Research Institute of America, Inc. (Chicago) and a Senior Vice President of Global Planning & Administration, Astellas Pharma Global Development. After those responsibilities, he became a Corporate Executive and a Japan & Asia Development Head. He developed Cephem antibiotics, antifungal agent Micafungin®, and led the clinical development of many drugs including immunosuppressant Prograf®, used for suppressing rejection reactions in organ transplantation.
As a research team, we recognize the importance of ethical principles of medical research and animal welfare, including its legal sides, considering the life-threatening factors of research field. Based on this recognition, we have established and currently operating the “Human organization research ethics committee” and “Animal experiment ethics committee”.
| Name | Belongs | Speciality |
|---|---|---|
| Ryuji Hiramatsu* | Non-exective director of NextGeM Inc. | Experts in natural sciences(R&D, Ph.D.) |
| Satoru Otsuru | The University of Maryland, Baltimore,USA | Experts in natural sciences(physician, plastic surgery, MD, Ph.D.) |
| Goh Ohji | Research center for urban safety and security, Kobe University | Experts in natural sciences(general internist, infectious disease, gastroenterology, endoscopist, MD) |
| Natsuko Shimizu | Shimizu Aragaki Law Office | Experts in humanities and social sciences(lawyer) |
| Minako Isogai | NextGeM Inc. | Experts in humanities and social sciences |
| Toko Shiotsuki | CyberAgent Inc. | Person representing the general position including the perspective of the research subject(Director (Audit Committee Member)) |
| Maya Ishitsuki | No affiliation | Person representing the general position including the perspective of the research subject |
*Committee chair
| Name | Belongs | Speciality |
|---|---|---|
| Ryuji Hiramatsu * | Non-exective director of NextGeM Inc. | Experts in natural sciences(R&D, Ph.D.) |
| Norimasa Sawada | Sapporo Medical University. | Experts in natural sciences(Professor Emeritus, Pathologist, M.D., Ph.D.) |
| Goh Ohji | Research center for urban safety and security, Kobe University | Experts in natural sciences(general internist, infectious disease, gastroenterology, endoscopist, MD) |
| Natsuko Shimizu | Shimizu Aragaki Law Office | Experts in humanities and social sciences(lawyer) |
| Minako Isogai | NextGeM Inc. | Experts in humanities and social sciences |
| Toko Shiotsuki | CyberAgent Inc. | Person representing the general position including the perspective of the research subject(Director (Audit Committee Member)) |
| Maya Ishitsuki | No affiliation | Person representing the general position including the perspective of the research subject |
*Committee chair
6-3-5 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047
Kobe Bio Lab. at KCMI
Kobe Bio Lab.(entrance)
Kobe Bio Lab.(floor)
1-5-13 Jinnan, Shibuya-ku, Tokyo 150-0041
